Clinicians say GLP-1 uptake forces obesity and eating disorder care together

Researchers at the University of Adelaide say the rapid spread of GLP-1 medicines such as Ozempic and Mounjaro is erasing the old line between obesity treatment and eating disorder treatment, because many patients now move between both kinds of care ^[1][2]. The findings come from work led by Professor Gemma Sharp, a clinical psychologist who studies eating disorders, body image and weight, published in the Journal of Eating Disorders ^[1].

Sharp says obesity and eating disorders have "more in common than many people realize" and that treating them as opposing conditions no longer fits how patients actually experience care ^[1][2]. She points out that most people with an eating disorder are not underweight, and many go undiagnosed because clinicians focus on weight rather than on the eating disorder itself ^[1][2].

The scale of overlap is notable in Australia, where the study was conducted: about one in three adults lives with obesity, and roughly 5% of Australians, or about 1.1 million people, have an eating disorder ^[1][2]. Early evidence suggests GLP-1 medicines may reduce binge-eating behavior in some people, but researchers say it remains unclear whether the drugs' appetite-suppressing effects could pose risks for people who already have an eating disorder ^[1][2].

Sharp and colleagues argue that GLP-1 drugs are "only one piece of the puzzle" and that the real work ahead is figuring out which patients are likely to benefit, which are at greater risk of harm, and how to build screening, monitoring and multidisciplinary care into routine prescribing ^[1][2]. The research group involved, the Consortium for Research in Eating Disorders, was created specifically to bring clinicians, researchers, people with lived experience and industry partners together on issues like this rather than treating obesity and eating disorders as separate silos ^[1][2].

Why it matters for patients

For people in the US taking or considering semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), or orforglipron (Foundayo), this research signals that clinicians are increasingly aware that a drug prescribed for weight loss can interact with an eating disorder a patient may not know they have, or may not have disclosed. Because most people with eating disorders are not underweight, the condition can be easy to miss during a routine weight-loss consultation ^[1][2].

The researchers are calling for eating disorder screening before and during GLP-1 therapy, plus shared care between weight-management and mental health providers ^[1][2]. That is a recommendation from academic researchers, not a rule. No guideline body has mandated such screening, so whether and how it happens still depends on individual clinicians and health systems.

The study also draws on Australian population data, not US figures, so the exact scale of overlap between obesity and eating disorders in the United States is not addressed in this research and remains unknown from these sources.

What happens next

The authors say the priority now is identifying which patients are most likely to benefit from GLP-1 medicines and which face greater risk of harm, and turning screening and multidisciplinary care into standard practice rather than an exception ^[1][2]. No specific timeline, US regulatory action, or professional society response is described in the available sources.